Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates

Miryana Radosevich, Thierry Burnouf

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The manufacture of coagulation Factor VIII concentrates fractionated from human plasma is subjected to a set of stringent quality control tests and quality assurance procedures. These requirements apply to all stages of product development and production, from the selection and quality control of the starting plasma source material to the purification, viral inactivation, storage and distribution phases of the final product in its pharmaceutical form. The present review addresses the major in-vitro and in-vivo analytical methods important to assess the potency, quality, and safety of coagulation Factor VIII products and to detect the presence of unwanted contaminants such as proteolytic enzymes and endotoxins.

Original languageEnglish
Pages (from-to)83-94
Number of pages12
JournalCurrent Pharmaceutical Analysis
Volume3
Issue number2
DOIs
Publication statusPublished - May 2007
Externally publishedYes

Fingerprint

Factor VIII
Biological Assay
Quality Control
Quality control
Assays
Virus Inactivation
Plasma (human)
Plasmas
Safety
Plasma sources
Quality assurance
Endotoxins
Product development
Purification
Peptide Hydrolases
Impurities
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • Analytical tests
  • Factor VIII
  • Human plasma
  • Quality control
  • Standards

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Biochemistry
  • Biophysics

Cite this

Biological and biochemical assays to ensure the quality and safety of plasma-derived products : Factor VIII concentrates. / Radosevich, Miryana; Burnouf, Thierry.

In: Current Pharmaceutical Analysis, Vol. 3, No. 2, 05.2007, p. 83-94.

Research output: Contribution to journalReview article

@article{e48ceeb58e29483ebad3e5b987c594a4,
title = "Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates",
abstract = "The manufacture of coagulation Factor VIII concentrates fractionated from human plasma is subjected to a set of stringent quality control tests and quality assurance procedures. These requirements apply to all stages of product development and production, from the selection and quality control of the starting plasma source material to the purification, viral inactivation, storage and distribution phases of the final product in its pharmaceutical form. The present review addresses the major in-vitro and in-vivo analytical methods important to assess the potency, quality, and safety of coagulation Factor VIII products and to detect the presence of unwanted contaminants such as proteolytic enzymes and endotoxins.",
keywords = "Analytical tests, Factor VIII, Human plasma, Quality control, Standards",
author = "Miryana Radosevich and Thierry Burnouf",
year = "2007",
month = "5",
doi = "10.2174/157341207780598959",
language = "English",
volume = "3",
pages = "83--94",
journal = "Current Pharmaceutical Analysis",
issn = "1573-4129",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Biological and biochemical assays to ensure the quality and safety of plasma-derived products

T2 - Factor VIII concentrates

AU - Radosevich, Miryana

AU - Burnouf, Thierry

PY - 2007/5

Y1 - 2007/5

N2 - The manufacture of coagulation Factor VIII concentrates fractionated from human plasma is subjected to a set of stringent quality control tests and quality assurance procedures. These requirements apply to all stages of product development and production, from the selection and quality control of the starting plasma source material to the purification, viral inactivation, storage and distribution phases of the final product in its pharmaceutical form. The present review addresses the major in-vitro and in-vivo analytical methods important to assess the potency, quality, and safety of coagulation Factor VIII products and to detect the presence of unwanted contaminants such as proteolytic enzymes and endotoxins.

AB - The manufacture of coagulation Factor VIII concentrates fractionated from human plasma is subjected to a set of stringent quality control tests and quality assurance procedures. These requirements apply to all stages of product development and production, from the selection and quality control of the starting plasma source material to the purification, viral inactivation, storage and distribution phases of the final product in its pharmaceutical form. The present review addresses the major in-vitro and in-vivo analytical methods important to assess the potency, quality, and safety of coagulation Factor VIII products and to detect the presence of unwanted contaminants such as proteolytic enzymes and endotoxins.

KW - Analytical tests

KW - Factor VIII

KW - Human plasma

KW - Quality control

KW - Standards

UR - http://www.scopus.com/inward/record.url?scp=34248994372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248994372&partnerID=8YFLogxK

U2 - 10.2174/157341207780598959

DO - 10.2174/157341207780598959

M3 - Review article

AN - SCOPUS:34248994372

VL - 3

SP - 83

EP - 94

JO - Current Pharmaceutical Analysis

JF - Current Pharmaceutical Analysis

SN - 1573-4129

IS - 2

ER -